pavurutamab

{
  "id": "MLC-T-ONC-015867",
  "term": "pavurutamab",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pavurutamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.",
  "synonyms": [
    "bispecific T-cell engager antibody AMG 701",
    "BiTE antibody AMG 701",
    "BCMA/CD3-directed bispecific T-cell engager antibody AMG 701",
    "anti-BCMA x anti-CD3 BiTE AMG 701",
    "anti-BCMA/CD3 BiTE antibody AMG 701"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pavurutamab/"
}